Antigen-Specific Microparticles for Tolerogenic Immune Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dendritic cell-based vaccines for autoimmune diseases face challenges such as ex-vivo manipulation risks, high costs, and suboptimal stability, requiring alternative compositions with improved stability and targeted delivery to immune cells.
Innovation Solution
Antigen-specific, tolerance-inducing microparticles are developed, comprising a polymeric matrix with encapsulated antigens and therapeutic agents, surface-modified with ligands to target immature dendritic cells, inducing tolerogenic DCs and Tregs, and promoting antigen-specific immunosuppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cell-based vaccines are used to promote tolerance, then immune suppression and Treg induction are improved, but patient safety risks and cost increase due to ex-vivo manipulation
Solution Approach 1:
The patent creates synthetic microparticles that copy the essential functions of dendritic cells (antigen presentation and tolerance induction) without requiring actual cell manipulation. These microparticles encapsulate antigens and present them in a tolerogenic manner, replicating the immune suppressive effects of DC-based vaccines while eliminating the need for ex-vivo cell handling and patient safety risks
Solution Approach 2:
The microparticles serve as an intermediary between the antigen and the immune system, mediating the tolerogenic response. Instead of directly manipulating dendritic cells, the microparticles act as a carrier that delivers antigens in a controlled manner to induce tolerance, thereby eliminating the harmful effects of cell manipulation while maintaining therapeutic efficacy
2Reliability
If dendritic cell-based vaccines are used to promote tolerance, then immune suppression is improved, but manufacturing cost increases
Solution Approach 1:
The patent employs synthetic microparticles that can be manufactured using inexpensive materials and standardized processes. These microparticles are designed to be stable, non-living entities that eliminate the need for complex cell culture facilities, specialized personnel, and costly quality control measures required for biological cell-based vaccines, thereby significantly reducing manufacturing costs
3Reliability
If dendritic cell-based vaccine compositions are used, then tolerance induction is achieved, but ex vivo stability decreases
Solution Approach 1:
The microparticles replicate the functional properties of dendritic cells (antigen encapsulation and presentation) while using stable synthetic materials instead of living cells. This copying approach maintains the tolerogenic capability while achieving superior ex vivo stability, as the microparticles do not require cell culture conditions and can be stored under standard pharmaceutical conditions
Solution Approach 2:
The patent transforms the biological system (living dendritic cells) into a synthetic system (microparticles) by changing the fundamental parameters of the vaccine composition. This transition from biological to synthetic materials dramatically improves ex vivo stability and shelf-life while maintaining the essential immune modulatory functions through controlled antigen presentation mechanisms
Data Source
AI summary
The present invention provides antigen-specific, tolerance-inducing microparticles for the targeted delivery of therapeutic agents to immune cells. In addition, the present invention allows for sustained release of therapeutic agents for a prolonged period of time. Also provided are therapeutic uses of the present invention for the prevention and/or treatment of immune diseases and autoimmune disorders. In a specific embodiment, the present invention provides treatment for type 1 diabetes.